Replies to post #174207 on Biotech Values

[biomaven0]

>>Shkreli seemed pretty confident Chenodal would work as well as Intercept’s drug for PBC & NASH

Hard for me to imagine that is true, even though I wish it was given I own RTRX in both real life and in the SI charity portfolio with a big weighting. 100x better potency (implying a much lower dose) very likely buys you some safety and tolerability advantages too.

See P9 of this presentation:

http://www.interceptpharma.com/pdf/Adorini.EASL.April2013.pdf

Aside from anything else, the pricing difference would make other indications very difficult.

Peter